New Hampshire SB 465: classifying xylazine as a schedule III controlled drug.

Bill Text

SB 465-FN - AS AMENDED BY THE SENATE

03/05/2026 0842s

2026 SESSION

 26-2002

 09/05

SENATE BILL 465-FN

AN ACT classifying xylazine as a schedule III controlled drug.

SPONSORS: Sen. Gannon, Dist 23; Sen. Abbas, Dist 22; Sen. Birdsell, Dist 19; Sen. Carson, Dist 14; Sen. Rochefort, Dist 1; Sen. McConkey, Dist 3; Rep. L. Walsh, Rock. 15; Rep. Vose, Rock. 5; Rep. Roy, Rock. 31; Rep. Rhodes, Ches. 17

COMMITTEE: Judiciary

─────────────────────────────────────────────────────────────────

ANALYSIS

 This bill classifies xylazine as a schedule III controlled drug.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 

Explanation: Matter added to current law appears in bold italics.

 Matter removed from current law appears [in brackets and struckthrough.]

 Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

03/05/2026 0842s 26-2002

 09/05

STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Twenty-Six

AN ACT classifying xylazine as a schedule III controlled drug.

Be it Enacted by the Senate and House of Representatives in General Court convened:

 1 New Section; Controlled Drug Act; Xylazine. Amend RSA 318-B by inserting after section 1-c the following new section: 

 318-B:1-d Xylazine.

 I. Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of the commissioner of the department of health and human services, xylazine shall be scheduled as a schedule III controlled drug.

 II. Notwithstanding paragraph I, nothing in this section shall prevent any licensed veterinarian, as defined in RSA 332-B:1, from doing any of the following: 

 (a) Dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. section 360b. 

 (b) Dispensing or prescribing for, or administering to, a nonhuman species that is permissible under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. section 360b(a)(4). 

 (c) Another use that is approved or permissible under the Federal Food, Drug, and Cosmetic Act.

 2 Effective Date. This act shall take effect January 1, 2027.

 LBA

 26-2002

 04/06/2026

SB 465-FN- FISCAL NOTE

AS AMENDED BY THE SENATE (AMENDMENT #2026-0842s)

AN ACT classifying xylazine as a schedule III controlled drug.

FISCAL IMPACT: 

 Estimated State Impact

FY 2026

FY 2027

FY 2028

FY 2029

 Revenue

$0

$0 

$0 

$0 

 Revenue Fund

None

 Expenditures*

Indeterminable

 Funding Source

General Fund

 Appropriations*

$0 

$0 

$0 

$0 

 Funding Source

None

 *Expenditure = Cost of bill *Appropriation = Authorized funding to cover cost of bill

 Estimated Political Subdivision Impact

FY 2026

FY 2027

FY 2028

FY 2029

 County Revenue

$0 

$0 

$0 

$0 

 County Expenditures

Indeterminable

 Local Revenue

$0 

$0 

$0 

$0 

 Local Expenditures

Indeterminable

METHODOLOGY:

This bill adds, deletes, or modifies a criminal penalty, or changes statute to which there is a penalty for violation. Therefore, this bill may have an impact on the judicial and correctional systems, which could affect prosecution, incarceration, probation, and parole costs, for the state, as well as county and local governments. A summary of such costs can be found at: https://gencourt.state.nh.us/lba/Budget/Fiscal_Notes/JudicialCorrectionalCosts.pdf

AGENCIES CONTACTED:

Judicial Branch, Judicial Council, Department of Justice, Department of Corrections, New Hampshire Association of Counties, and New Hampshire Municipal Association